Virus purification
Inventors
Barbero Calzado, Jana • Nebenführ, Mario • Schiegl, Robert • Weber, Michael • HEINDL-WRUSS, Jürgen
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Described herein are processes for purifying infectious virus particles and uses of protamine in such processes.
Core Innovation
The methods purify and separate infectious Chikungunya virus particles from crude harvests containing non-infectious particles and cell-substrate impurities. Contacting the crude harvest with an agent comprising protamine selectively precipitates and depletes non-infectious, immature, and aggregated virus particles alongside host-cell impurities, while retaining infectious-virus titers. The resulting preparations exhibit enrichment of infectious Chikungunya virus particles relative to total virus particles and undergo subsequent size-based purification.
The disclosure further encompasses immunization compositions and vaccines comprising Chikungunya virus with a deletion mutation in non-structural protein 3 or an immunogenic variant thereof. These immunization compositions are defined by specified particle-size characteristics and particle infectivity thresholds. Additionally, the disclosure describes protamine treatment applied to Zika virus preparations to achieve active-virus recovery and reduce residual host-cell impurities.
Claims Coverage
The claims encompass four inventive features across independent claims directed to virus separation, purification methods, and immunization compositions.
Separation of infectious and non-infectious Chikungunya virus particles
A method for separating infectious Chikungunya virus particles from non-infectious Chikungunya virus particles by precipitating the non-infectious virus particles with an agent comprising protamine.
Purification of infectious Chikungunya virus particles from crude harvest
A method for purifying infectious Chikungunya virus particles from a crude harvest containing infectious and non-infectious particles and cell-substrate impurities, contacting the harvest with an agent comprising protamine to produce a preparation enriched in infectious particles relative to total Chikungunya virus particles.
Immunization composition defined by particle size
A composition for immunization against a Chikungunya virus infection comprising a Chikungunya virus with a deletion mutation in non-structural protein 3 or an immunogenic variant thereof, wherein at least 50% of the Chikungunya virus particles are in the size range of 20 to 40 nm.
Immunization composition defined by infectious particles
A composition for immunization against a Chikungunya virus infection comprising a Chikungunya virus with a deletion mutation in non-structural protein 3 or an immunogenic variant thereof, wherein at least 50% of the Chikungunya virus particles are infectious.
The claim coverage encompasses protamine-mediated separation and purification of infectious Chikungunya virus particles from crude harvests, as well as immunization compositions defined by particle size and particle infectivity thresholds.
Stated Advantages
Enrichment of infectious Chikungunya virus particles relative to total Chikungunya virus particles.
Selective precipitation, removal, or depletion of host-cell impurities, low-molecular-weight material, non-infectious, immature, and aggregated particles while retaining infectious virions and virus titers.
Production of a purified pool with low residual host-cell DNA and protein.
High active-virus recovery following protamine treatment in Zika virus preparations.
Documented Applications
Purification and separation of infectious Chikungunya virus particles from crude harvests, including particles produced on cell substrates such as Vero cells.
Manufacture of compositions and vaccines for immunization against Chikungunya virus infection, including preparations comprising attenuated Δ4nsP3 Chikungunya virus.
Protamine treatment of Zika virus and preparation of inactivated Zika virus vaccines.
Interested in licensing this patent?